Items tagged with Research and development

Antibiotic resistance: Why aren’t drug companies developing new medicines to stop superbugs? (post with simple image)

Antibiotics are a critical class of drugs that have failed to earn much investment by pharmaceutical companies in recent years. The industry cites their lack of profitability, so the U.S. government is stepping in with incentives and quick regulatory approvals.

As first EU Ministerial meeting on tuberculosis closes, MSF calls on the EU to triple funding for TB R&D (post with simple image)

Médecins Sans Frontières calls on the European Union to take concrete actions to boost the regional fight against TB, including tripling European funding for research and development.

TB R&D’s shift to the left (post with simple image)

As the Bill & Melinda Gates Foundation realigns its TB vaccine strategy to focus on early-stage candidate development, equitable access priorities must also be established before large-scale trials are conducted.

Letter from TB community re: intellectual property rights to sutezolid (post with simple image)

The letter urges Johns Hopkins to assure the timely and responsible development of TB drug candidate sutezolid if transferring any intellectual property rights to Sequella.

Report: Securing new drugs for future generations: The pipeline of antibiotics (post with simple image)

The report provides a high-level assessment of the development pipeline for new antibiotics, and sets out the Review’s initial proposals for the action needed at a global level to kick-start antibiotic drug discovery efforts.

TB community reiterates request to Johns Hopkins to review sutezolid licensing agreement with Sequella (post with simple image)

The TB CAB and TAG restate their request to Johns Hopkins University to allow representatives of TB-affected communities to comment on the terms of any agreement with Sequella before it is finalized.

Tuberculosis R&D “grossly insufficient” according to new report (post with simple image)

With just $255 million spent on TB research and development each year, funding is currently just one-third of the annual target set by the Global Plan to Stop TB 2011-2015.

Appeal to develop VXc-486 for tuberculosis (post with simple image)

Advocates urge Vertex to assure the timely and responsible development of drug candidate VXc-486 for tuberculosis.

The FDA’s concession conundrum (post with simple image)

Can regulatory incentives promote responsible TB drug development?

Page 13 of 17 · Total posts: 0

←First 12 13 14 Last→